Horizontal Consolidation: Antitrust Laws, Review, and Remedies

Horizontal consolidation is the combination of two companies that compete directly in the same industry and at the same stage of production, such as two regional grocery chains, two semiconductor makers, or two airlines merging into one. Federal antitrust law treats these deals with the closest scrutiny of any transaction type, because each one removes an independent rival from the market. The Federal Trade Commission and the Department of Justice review deals above $133.9 million in value (as of 2026) and can block any transaction they believe will significantly reduce competition or push prices higher.

Why Companies Combine With Their Competitors

The economic logic is straightforward. Combining overlapping operations cuts costs: redundant warehouses close, duplicate administrative departments merge, and the combined purchasing power grows. The larger entity negotiates better deals with suppliers and spreads fixed costs across a bigger revenue base.

Those savings come with a trade-off regulators watch closely. Every horizontal deal eliminates a competitor, and on the ground the combination also means job cuts, facility closures, and the difficult work of merging IT systems, sales territories, and corporate cultures. When integration is done, the surviving company controls a larger share of industry revenue and faces fewer rivals for the same customers. This is what separates horizontal deals from vertical integration, where a company acquires a supplier or distributor along its supply chain rather than a competitor beside it.

The Antitrust Laws That Apply

Three federal statutes do the work of merger enforcement in the United States. Each addresses the same underlying concern from a different angle: preventing any single company from gaining enough market power to raise prices, degrade quality, or slow innovation without competitive consequences.

The Sherman Antitrust Act

Section 1 declares illegal any contract, combination, or conspiracy that restrains interstate or foreign trade. Courts read this to prohibit only unreasonable restraints, so the government has to show actual harm to competition rather than mere inconvenience to a rival. Section 2 makes it a felony to monopolize or attempt to monopolize any part of trade. Corporate violators face fines up to $100 million; individuals face fines up to $1 million and up to 10 years in prison.¹²

The Clayton Antitrust Act

Section 7 of the Clayton Act is the merger-specific statute. It bars any acquisition of stock or assets where the effect “may be substantially to lessen competition, or to tend to create a monopoly.”³ The word may is what gives the statute its reach. Regulators do not have to prove a deal has already harmed anyone; they can challenge it before closing based on the probability of future harm.

Section 4 of the same act opens the courthouse door to private parties. Any person injured by an antitrust violation can sue and recover three times their actual damages plus attorney’s fees.⁴

The FTC Act

Section 5 of the FTC Act prohibits “unfair methods of competition,” giving the FTC an independent basis to challenge deals that do not fit cleanly under Sherman or Clayton.⁵ It functions as a backstop when a transaction raises competitive concerns the other statutes reach only indirectly.

How Regulators Measure the Competitive Effect

Merger review is not purely a judgment call. The FTC and DOJ quantify how concentrated a market is before and after a proposed deal using the Herfindahl-Hirschman Index, which squares the market share of every firm in the relevant market and sums the results.⁶ Higher scores mean fewer firms hold more of the market. What matters most is how much the HHI moves because of the deal, not just its final level.

The Thresholds That Trigger a Presumption

The 2023 Merger Guidelines, jointly issued by the DOJ and FTC and still in effect for 2026, set specific numerical triggers. A market with an HHI above 1,800 is considered highly concentrated. An increase of more than 100 points from a single deal counts as significant. When both conditions are met, the merger is presumed to substantially lessen competition.⁷

A separate presumption kicks in when a deal creates a firm controlling more than 30% of the market, provided the HHI also rises by more than 100 points.⁷ These presumptions are rebuttable, but the burden shifts to the merging companies to prove the deal will not harm competition. In practice, crossing either line makes a deal much harder to close.

Effects Beyond Price

Price is not the only variable. When companies with overlapping research and development programs combine, the merged firm may have less reason to pursue competing product lines. Agencies look at whether a deal will reduce product variety, degrade service quality, or discourage investment in new technology. Hospital mergers, for example, have been challenged partly on evidence that reduced competition led to worse clinical outcomes rather than just higher bills.

The Premerger Notification Process

The Hart-Scott-Rodino Antitrust Improvements Act requires companies to notify both the FTC and the DOJ before closing deals that meet certain dollar thresholds. For 2026, the minimum transaction value that triggers a mandatory filing is $133.9 million, effective February 17, 2026.⁸ The thresholds adjust each year for inflation, so the correct figure is whichever is in effect on the closing date.⁹

Filing Fees

The fee scales with transaction value. The 2026 tiers, effective February 17, 2026, are:⁸

$35,000 for transactions valued under $189.6 million
$110,000 for $189.6 million to under $586.9 million
$275,000 for $586.9 million to under $1.174 billion
$440,000 for $1.174 billion to under $2.347 billion
$875,000 for $2.347 billion to under $5.869 billion
$2,460,000 for $5.869 billion or more

The Waiting Period and Second Requests

Once the agencies receive a completed filing, a mandatory 30-day waiting period begins, or 15 days for cash tender offers.⁹ Only one agency reviews any given deal. Its staff economists and lawyers use the window to decide whether the transaction warrants a deeper look.

If they see problems, the reviewing agency issues a Second Request, a formal demand for internal documents, strategic plans, and sales data. The waiting period pauses entirely and only restarts when the companies certify substantial compliance. The agency then gets another 30 days. Complying is expensive; companies routinely spend months and tens of millions of dollars producing records. If the agency concludes the deal is unlawful, it can negotiate a settlement or file suit in federal court to block it.

Defenses the Merging Companies Can Raise

Crossing a concentration threshold does not automatically end a deal. Two defenses come up most often.

The Efficiency Defense

The parties can argue that cost savings or quality gains outweigh the loss of competition. To count, the claimed efficiencies must be merger-specific (meaning the same savings cannot be reached through a less anticompetitive route like a joint venture or licensing), verifiable with concrete evidence rather than projection, and not the product of simply cutting output or service.¹⁰ The agencies apply a sliding scale: the worse the competitive effects, the larger and more credible the efficiencies must be. Efficiency claims almost never save a deal that would create a monopoly or near-monopoly.

The Failing Firm Defense

If one of the merging companies is genuinely about to fail, the deal may be permitted even in a concentrated market, because those assets would exit anyway. The Supreme Court set three requirements:

Imminent failure. The firm must face the “grave probability of business failure” and be unable to meet its near-term obligations. Declining sales alone do not qualify.
No viable reorganization. A Chapter 11 restructuring must be unlikely to succeed.
No less harmful buyer. The firm must have made good-faith efforts to find an alternative purchaser that would pose less competitive risk, and any offer above liquidation value counts as a reasonable alternative.

The defense is invoked often and succeeds rarely. Agencies are skeptical because companies in distress have strong incentives to overstate urgency, and the defense would lock in a permanent structural change to the market based on one firm’s temporary troubles.⁷

What Happens When Regulators Object

When an agency concludes a deal would harm competition, it has three main tools. The choice depends on whether the problem can be cut out surgically or whether the whole transaction is anticompetitive.

Structural Remedies

The most common fix is a divestiture: the parties sell off specific assets, product lines, or business units before closing so a competitor can be created or strengthened to replace the rivalry the deal would eliminate. A consent decree spells out which assets go, what transitional support the buyer receives, and how long the sale can take.

Behavioral Remedies

Sometimes the agency lets a deal close but imposes ongoing conduct rules: mandatory technology licensing, restrictions on certain pricing practices, or firewalls between business units. These are less disruptive than divestiture but harder to monitor and enforce over time, especially in industries where conditions shift quickly.

Blocking the Deal

If no remedy can address the harm, the agency sues in federal court for a preliminary injunction. If the court grants it, the deal is usually finished. Most companies abandon the transaction rather than litigate through a full trial; appeals are possible, but the timeline and uncertainty typically make walking away the practical choice.

Private Antitrust Lawsuits

Government enforcement is only one channel. Competitors, customers, and suppliers financially harmed by an anticompetitive merger can sue under Section 4 of the Clayton Act and recover three times their actual damages plus attorney’s fees.⁴ The treble-damages multiplier makes these suits financially attractive for plaintiffs and provides deterrence beyond what the agencies deliver on their own. A deal the FTC and DOJ let through can still face private litigation from anyone it harmed.

1
Office of the Law Revision Counsel. 15 USC 1 – Trusts, Etc., in Restraint of Trade Illegal; Penalty
2
Office of the Law Revision Counsel. 15 USC 2 – Monopolizing Trade a Felony; Penalty
3
Office of the Law Revision Counsel. 15 USC 18 – Acquisition by One Corporation of Stock of Another
4
Office of the Law Revision Counsel. 15 USC 15 – Suits by Persons Injured
5
Federal Trade Commission. A Brief Overview of the Federal Trade Commission’s Investigative and Law Enforcement Authority
6
Department of Justice: Antitrust Division. Herfindahl-Hirschman Index
7
Federal Trade Commission. Merger Guidelines
8
Federal Trade Commission. New HSR Thresholds and Filing Fees for 2026
9
Office of the Law Revision Counsel. 15 USC 18a – Premerger Notification and Waiting Period
10
U.S. Department of Justice Archives. The Merger Guidelines and the Integration of Efficiencies into Antitrust Review of Horizontal Mergers